UK media: traditional Chinese medicine enterprise to develop new drugs against ebola is still in development phase 
 
 
The 2014-10-10 13:45:23 

 
Source: xinhua The author: 

        According to the financial times reported net, China one of the leading generics firms bought Chinese military research and development of commercial rights of an experimental drug ebola, although medical experts said that the drug is still in the early stage of development. 
 
        By Morgan Stanley's private equity fund sihuan pharmaceutical holdings, is one of the largest supplier of prescription medicine hospitals in China. Sihuan pharmaceutical 8 announced late, it has to the Chinese military academy of medical sciences (hereinafter referred to as "JunKeYuan") to pay 10 million yuan technology transfer and drug development fee, and will work with JunKeYuan development which is developed by jk - 05 against ebola virus drugs. 
 
        This new drug is about 15 kinds of experimental drugs against ebola virus, one of these laboratories around the world for cell culture and animal experiments proved that have a certain effect. West Africa nearly 4000 people have been killed in the ebola outbreak. In addition, there are more than ten kinds of vaccines to prevent infections are safety and effect assessment. 
 
        The world health organization is working with international partners, in the worst outbreak of countries such as Liberia, sierra leone and guinea of clinical trials, the most promising drug fast arrangements despite the test procedure and what drugs will put to test is still unknown. 
 
        Max Planck biopharmaceutical company of California mixture ZMapp development of three kinds of antibody, so far the most reports. Its one of the few available dose in August was used in 7 patients, including four infected western medical workers in west Africa, but now in a state of out of stock. 
 
        A spokesman of sihuan pharmaceutical made it clear that the company intends to jk - 05 developed for a broad spectrum of antiviral drugs, except against ebola virus, also can deal with, yellow fever and other flu viruses. The company said that the drug has a "huge" market potential, especially in fighting the flu spread in China. 
 
        Sihuan pharmaceutical founder was a doctor, in the 1990 s in the booming southern city of shenzhen into the pharmaceutical industry. In 2001, they created the sihuan pharmaceutical, then took over the company JunKeYuan near Beijing pharmaceutical factory. 
 
        "The two sides will work together, as soon as possible to the marketed drugs, and realize industrialization," sihuan pharmaceutical chairman and chief executive of car Feng Sheng said in a statement. 
 
        Said in a statement, the drug "has passed the health expert review, obtain the special drug approval documents", and "key technical measures for prevention and control the ebola outbreak in China". 
 
        But in published clinical trials usually information administration of China's state food and drug supervision and administration of the site, not the drug clinical data. JunKeYuan no public comment. 
 
        China is eager to become one of the first developed the ebola treatment, solidifying its and may be affected by the outbreak of the relationship between the African countries. But Chinese medicine experts said the lack of access to information about the drug means that the outside world is difficult to assess the prospects. 
 
        "Sihuan pharmaceutical business is jk - 05 news may speed up the schedule of the drug into use in Africa, but I still don't believe it can be available in six months," said Yang of the autumn of the medical virology research institute, wuhan university. 
 
        "China does not have the living specimen of the ebola virus can study, imported virus living to China studies is in the list of banned. Chinese researchers have done, not based on the research of live virus, but rather from the GenBank database - virus gene sequence, thus producing cloned virus, then carries on the research," he said. 
 
        Specializes in Chinese medical market experts, George bader said: "in general, only let drugs in clinical trials and through registration - even with quick access to China's food safety, even if the drug only approved by the local Chinese, often also need at least five years." 
 
        Although r&d ebola vaccine efforts continue to push outside China, but the head of the Chinese center for disease control in radio official said in August, China there is no vaccine research and development related laboratory as needed.
 
 
The original link: http://mil.chinanews.com/gj/2014/10-10/6663302.shtml